Search Results - "Brail, L"

Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer by Schaefer, E, Braiteh, F, Forster, M, Talbot, D, Chandler, J, Richards, D, Andre, V, Estrem, S, Pitou, C, Tiu, R, Brail, L, Nikolinakos, P

“…Background: Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer, and carboplatin (C) and etoposide (E), the standard treatment for…”
Get full text

594 A Phase I Dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of LY2940680, an Oral Smo Inhibitor by Bendell, J, Weiss, G, Infante, J, Ramanathan, R, Jones, S, Korn, R, Burris, H, Brail, L, Jones, E, Von Hoff, D

Get full text

62 Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer by Geeganage, S, Sams, L, Joseph, S, Shepherd, T, Dally, R, Brail, L, Wang, T, Capen, A, Rodgers, G, Perkins, E

Get full text

Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors by McKean, M., Barve, M., Hong, D., Parikh, A., Rosen, E., Yang, J., Picard, R., Yi, J., Brail, L., Vecchio, D., Meniawy, T., John, T., Wang, J.

Get full text

Gene expression in individual cells : analysis using global single cell reverse transcription polymerase chain reaction (GSC RT-PCR) by BRAIL, L. H, JANG, A, BILLIA, F, ISCOVE, N. N, KLAMUT, H. J, HILL, R. P

“…The determination of the gene expression pattern of single cells has important implications for many areas of cellular and developmental biology including…”
Get full text

399 - Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer by Schaefer, E., Braiteh, F., Forster, M., Talbot, D., Chandler, J., Richards, D., Andre, V., Estrem, S., Pitou, C., Tiu, R., Brail, L., Nikolinakos, P.

Get full text

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours by Hollebecque, Antoine, Houédé, Nadine, Cohen, Ezra E.W, Massard, Christophe, Italiano, Antoine, Westwood, Paul, Bumgardner, William, Miller, Joel, Brail, Les H, Benhadji, Karim A, Soria, Jean-Charles

“…Abstract Background LY2584702 tosylate (hereafter referred to as LY2584702) is an oral, selective ATP competitive inhibitor of p70 S6 kinase. Preclinical…”
Get full text

A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY) by Limentani, S. A., Burris, H., Anderson, A. P., Brail, L. H., Satonin, D., Gueorguieva, I., Jones, S., Infante, J. R., Bendell, J. C.

“…Abstract only…”
Get full text

A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin by Brail, L. H., Gray, J. E., Burris, H., Simon, G. R., Cooksey, J., Jones, S. F., Farrington, D., Lam, T., Jackson, K., Chow, K., Brandt, J. T., Infante, J. R.

“…Abstract only…”
Get full text

Improved polymerase fidelity in PCR-SSCPA by Brail, L, Fan, E, Levin, D B, Logan, D M

“…Polymerase fidelity is important in any application of the polymerase chain reaction (PCR). In single-strand conformation polymorphism analysis (SSCPA) where…”
Get more information

Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors by Schwartz, Gary K, Weitzman, Aaron, O'Reilly, Eileen, Brail, Les, de Alwis, Dinesh P, Cleverly, Ann, Barile-Thiem, Barbara, Vinciguerra, Vincent, Budman, Daniel R

“…LY293111, a novel diaryl ether carboxylic acid derivative, is a potent and selective inhibitor of the lipoxygenase pathway either directly through…”
Get full text

Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma by Janne, P. A., Paz-Ares Rodriguez, L., Gottfried, M., Reaume, M. N., Kaukel, T., Oh, Y. W., Sykes, A., Enas, N., Brail, L. H., Von Pawel, J.

“…Abstract only 7024 Background: The eicosanoid pathway is altered in NSCLC. Pharmacological activators of peroxisome proliferator-activated receptor-gamma…”
Get full text

174 Correlation between protein kinase C-beta expression and patient survivals in primary tumors — implications for clinical drug development by Li, D., Phong, M., Lahn, M., Thornton, D., Brail, L., Ganji, G., Liao, B.

Get full text

Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines by Brail, L H, Hill, R P

“…Secretion of plasminogen activators (PA) has been shown to be an important method by which cells can initiate degradation of the extracellular matrix (ECM). In…”
Get full text

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection by Bristow, R G, Brail, L, Jang, A, Peacock, J, Chung, S, Benchimol, S, Hill, R P

“…Changes in wild-type p53 protein function occur in the majority of human tumors, and may alter genomic stability and the cellular response to ionizing…”
Get more information